Curie Therapeutics Appoints Karen Smith, M.D., Ph.D., as Independent Board Director

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Curie Therapeutics Inc. (“Curie”), a biotechnology company focused on developing innovative radiopharmaceutical therapies for oncological diseases, announced today that it has appointed Karen Smith, M.D., Ph.D., M.B.A., L.L.M., to its Board of Directors.

“It is with much excitement that we welcome Karen to our Board of Directors to provide additional diversity of thought and development experience,” said Simon Read, Curie’s CEO and founder. “Karen’s depth of knowledge in oncology drug development, experience on platform and asset-focused company boards, and background spanning medicine, law, and business, will serve us well as we advance our first precision radiopharmaceuticals into the clinic.”

“With a team of seasoned experts across its core capabilities and a mission to deliver an oncology drug profile that has not yet been achieved with existing modalities, Curie is uniquely poised to usher in a new era for precision radiopharmaceuticals,” said Dr. Smith. “Together we’ll build and advance a pipeline of radiopharmaceuticals designed to maximize potency, selectivity, and stability, while also achieving rapid systemic clearance. I believe Curie’s approach has the potential to result in powerful, novel treatments for patients suffering from solid tumors of high unmet need.”

Dr. Smith has overseen numerous trials and regulatory approvals leading to global product launches of small molecules, biologics and devices across oncology and other therapeutic areas. She is an accomplished executive who has led departments within large pharma (Allergan, Astra-Zeneca, Bristol Myers Squibb), and served as CMO or CEO at notable biotech companies (Jazz, ECI, Novosteo). She currently serves on the boards of Antares Pharma, Sangamo Therapeutics and Emyria Ltd. and has helped guide several successful corporate exits through acquisition (Forward Pharma, Sucampo Pharma, Acceleron Pharma). Dr Smith’s credentials include a B.App.Sc. with a double major in Biotechnology and Haematology; an M.D.; a Ph.D. in oncology molecular genetics; an M.B.A. and a Master of Law (L.L.M.).

About Curie Therapeutics

Curie Therapeutics is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted radiopharmaceuticals that are both safe and effective. Curie’s radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets, to deliver alpha and beta-emitting radionuclide payloads. Curie’s mission is to revolutionize the use of radiomedicines in cancer. Learn more at www.curietherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220308005444/en/

Argot Partners

Media: Sarah Sutton

IR: Kevin Murphy

curie@argotpartners.com

212.600.1902

Source: Curie Therapeutics Inc.